St. Jude Medical (STJ) : Vertex One Asset Management added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 439,077 shares of St. Jude Medical which is valued at $36,724,400 , the company said in a statement filed on Aug 12, 2016 with the SEC.St. Jude Medical makes up approximately 5.90% of Vertex One Asset Management’s portfolio.
Other Hedge Funds, Including , Cornerstone Capital Management Holdings. reduced its stake in STJ by selling 184,020 shares or 74.48% in the most recent quarter. The Hedge Fund company now holds 63,046 shares of STJ which is valued at $5,273,167. St. Jude Medical makes up approx 0.04% of Cornerstone Capital Management Holdings.’s portfolio.Atlantic Trust Group reduced its stake in STJ by selling 400 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 28,935 shares of STJ which is valued at $2,420,123. St. Jude Medical makes up approx 0.02% of Atlantic Trust Group’s portfolio.Canada Pension Plan Investment Board boosted its stake in STJ in the latest quarter, The investment management firm added 1,010,899 additional shares and now holds a total of 1,130,552 shares of St. Jude Medical which is valued at $94,559,369. St. Jude Medical makes up approx 0.36% of Canada Pension Plan Investment Board’s portfolio.Royal London Asset Management Ltd reduced its stake in STJ by selling 7,865 shares or 7.71% in the most recent quarter. The Hedge Fund company now holds 94,156 shares of STJ which is valued at $7,864,851. St. Jude Medical makes up approx 0.12% of Royal London Asset Management Ltd’s portfolio.
St. Jude Medical opened for trading at $78.27 and hit $78.64 on the upside on Monday, eventually ending the session at $78.25, with a gain of 0.31% or 0.24 points. The heightened volatility saw the trading volume jump to 91,16,633 shares. Company has a market cap of $22,296 M.
On the company’s financial health, St. Jude Medical reported $1.06 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $1.06. The company had revenue of $1562.00 million for the quarter, compared to analysts expectations of $1552.79 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Investors should note that on Aug 3, 2016, St. Jude Medical announced a cash dividend of $0.3100. The company’s management has announced Sep 28, 2016 as the ex-dividend date and fixed the record date on Sep 30, 2016. The payable date has been fixed on Oct 28, 2016.
Many Wall Street Analysts have commented on St. Jude Medical. Company shares were Downgraded by Wedbush on Jul 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 84 from a previous price target of $70 .St. Jude Medical was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016.
St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).